Wilson Disease (WD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036

Wilson Disease Market Outlook and Forecast

Thelansis's "Wilson Disease (WD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wilson Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Wilson Disease Overview

Wilson disease is an autosomal recessive disorder caused by pathogenic variants in ATP7B, which encodes a copper-transporting ATPase required for biliary copper excretion. Impaired ATP7B function causes copper accumulation in the liver and, with progression, the brain, cornea, and other tissues. Clinical manifestations vary and may include hepatitis, cirrhosis, acute liver failure, tremor, dystonia, dysarthria, movement disorders, psychiatric symptoms, and Kayser-Fleischer rings. Treatment aims to remove excess copper and prevent further accumulation using penicillamine, trientine, and/or zinc. Liver transplantation is reserved for selected patients with acute liver failure or advanced liver disease. Despite effective therapies, lifelong treatment, adherence demands and persistent neurological symptoms remain challenges. These limitations are driving development of disease-modifying strategies, including ATP7B gene replacement and gene-editing approaches such as UX701 and PM577a.

Key Highlights

• In the United States, diagnosed Wilson disease cases are estimated at 7,574 in 2026.
• Wilson disease is a rare inherited disorder that causes copper accumulation in the liver, brain, and other organs.
• Delayed diagnosis can lead to serious hepatic and neurological complications.
• Unmet need remains for treatments that improve copper control and support long-term organ health.

Market Overview

• The Italy Wilson disease market is projected to grow from $25M in 2026 to $33M by 2036.
• Market growth is driven by:
• Continued use of copper-lowering therapies and improved disease management
• Advances in diagnosis and development of novel treatment approaches
• Future growth will depend on therapies that offer effective long-term copper control, improved tolerability, and better patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Lingyi Biotech Co., Ltd.
• Orphalan
• Ultragenyx Pharmaceutical Inc.
• Prime Medicine, Inc.
• Nobelpharma